BridgeBio Pharma (BBIO) vs TG Therapeutics (TGTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
TG Therapeutics (TGTX) has outperformed BridgeBio Pharma (BBIO) over the past year, gaining 98.2% versus a gain of 11.6%. Over five years, TGTX leads with a +164.1% price change compared with +92.2% for BBIO. BridgeBio Pharma is the larger company by market cap ($14.81 billion vs $9.57 billion), about 1.5 times the size.
TG Therapeutics converts more of its revenue into profit, with a net margin of 72.6% versus -146.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBIO | TGTX |
|---|---|---|
| Share price | $76.03 | $63.34 |
| Market cap | $14.81B | $9.57B |
| 1-day change | -2.75% | -2.37% |
| YTD return | -0.60% | +112.48% |
| 1-year return | +11.63% | +98.25% |
| 5-year return | +92.24% | +164.14% |
| P/E ratio (TTM) | — | 94.54 |
| Forward P/E | — | 24.81 |
| EPS (TTM) | $-3.03 | $0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $502.08M | $616.29M |
| Revenue growth (YoY) | +126.26% | +87.32% |
| Net income (latest FY) | $-732.94M | $447.18M |
| Gross margin | 95.82% | 83.66% |
| Operating margin | -104.25% | 20.01% |
| Net margin | -145.98% | 72.56% |
| 52-week high | $93.42 | $68.03 |
| 52-week low | $62.50 | $26.76 |
| Distance from 52-week high | -18.61% | -6.89% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +40.73% | +9.61% |
| Average volume | 2.67M | 1.86M |
| Shares outstanding | 194.80M | 151.15M |
| Employees | 1,081 | 399 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TGTX has outperformed BBIO by 86.6 percentage points over the past year.
- TG Therapeutics is more profitable, keeping 72.6 cents of every revenue dollar as net income versus -146.0 cents for BridgeBio Pharma.
- BridgeBio Pharma grew revenue faster in its latest fiscal year (+126.26% vs +87.32%).
About BridgeBio Pharma
BBIO stock →BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,081 employees
About TG Therapeutics
TGTX stock →TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 399 employees
BBIO vs TGTX FAQ
Which is bigger, BridgeBio Pharma or TG Therapeutics?
BridgeBio Pharma (BBIO) is larger, with a market capitalization of $14.81B compared with $9.57B for TG Therapeutics (TGTX).
Which stock has performed better over the past year, BBIO or TGTX?
TGTX returned +98.25% over the past 12 months, compared with +11.63% for BBIO (price return, excluding dividends). Past performance does not predict future results.
Are BridgeBio Pharma and TG Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.